Cartalax
Cartilage bioregulator peptide
Cartilage tissue bioregulator.
Half-life
~ hours
Mol. weight
~ 347.3 g/mol
Sequence
Ala-Glu-Asp (AED)
Discussions
0 threads
Overview
A short bioregulator peptide studied for regulating gene expression in cartilage tissue, with proposed support for chondrocyte function and joint-cartilage health. It applies the Khavinson bioregulator framework to articular cartilage — a tissue with notoriously limited self-repair capacity.
Mechanism of action
Cartalax is a bioregulator peptide studied for regulating gene expression in cartilage tissue, with proposed support for chondrocyte function. Articular cartilage is avascular and heals poorly, making it a logical target for a bioregulator aimed at supporting the cells that maintain it. The mechanism — ultra-short peptide transcriptional modulation — is the same framework as the broader bioregulator class.
Researched benefits
- Studied for cartilage/joint support
- Targets chondrocytes (cartilage cells)
- Short bioregulator format
Considerations
- Cartilage heals poorly regardless of approach
- Evidence concentrated in one tradition
- Human data limited
Key Academic Literature & Studies
Search more in PubMedPeer-reviewed citations and clinical trials evaluating Cartalax in scientific literature.
Query PubMed for recent peer-reviewed preclinical and clinical publications on Cartalax:
View Cartalax index on PubMed (NCBI)